Cancer immunotherapy company Immatics receives 100th US patent
Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.
This is a significant achievement for the Company and demonstrates the breadth of Immatics’ innovation power and the quality of its science. Immatics’ strong patent portfolio enables the Company to develop its pipeline of cancer immunotherapies, to protect Immatics’ innovations and to safeguard the Company’s technology investments.
Read press release here.